Overexpression of c-kit protein is an infrequent event in small cell carcinomas of the uterine cervix

Modern Pathology

Volumn 17, Issue 6, 2004, Pages 732-738

  Wang, Hanlin L ^a   Lu, Danielle W ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HUNTINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

c kit; CD117; Cervix; Small cell carcinoma

Indexed keywords

IMATINIB; POLYCLONAL ANTIBODY; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; LUNG CARCINOGENESIS; LUNG SMALL CELL CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL CELL CARCINOMA; STAINING; UTERINE CERVIX CARCINOMA;

ADULT; AGED; CARCINOMA, SMALL CELL; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; STROMAL CELLS; UTERINE CERVICAL NEOPLASMS;

EID: 2642574285     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800112     Document Type: Article

References (58)

1. Gibson PC, Cooper K. CD117 (KIT): a diverse protein with selective applications in surgical pathology. Adv Anat Pathol 2002;9:65-69.
2. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-465.
3. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002;38(Suppl 5): S39-S51.
4. Heinrich MC, Rubin BP, Longley BJ, et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002;33:484-495.
5. Dematteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33:466-477.
6. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
7. Radford IR. Imatinib. Novartis. Curr Opin Investig Drugs 2002;3:492-499.
8. Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-1703.
9. Natali PG, Nicotra MR, Sures I, et al. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 1992;52:6139-6143.
10. Matsuda R, Takahashi T, Nakamura S, et al. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol 1993;142:339-346.
11. Tsuura Y, Hiraki H, Watanabe K, et al. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch 1994;424:135-141.
12. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 1998;29:498-504.
13. Naeem M, Dahiya M, Clark JI, et al. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum Pathol 2002;33:1182-1187.
14. Micke P, Basrai M, Faldum A, et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res 2003;9:188-194.
15. Potti A, Moazzam N, Ramar K, et al. CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. Ann Oncol 2003;14:894-897.
16. Lonardo F, Pass HI, Lucas DR. Immunohistochemistry frequently detects c-Kit expression in pulmonary small cell carcinoma and may help select clinical subsets for a novel form of chemotherapy. Appl Immunohistochem Mol Morphol 2003;11:51-55.
17. Burger H, den Bakker MA, Stoter G, et al. Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer 2003;39:793-799.
18. Sekido Y, Takahashi T, Ueda R, et al. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res 1993;53:1709-1714.
19. Hibi K, Takahashi T, Sekido Y, et al. Coexpression of the stem cell factor and, the c-kit genes in small-cell lung cancer. Oncogene 1991;6:2291-2296.
20. Sekido Y, Obata Y, Ueda R, et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 1991;51:2416-2419.
21. Rygaard K, Nakamura T, Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 1993;67:37-46.
22. Plummer III H, Catlett J, Leftwich J, et al. c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res 1993;53:4337-4342.
23. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996;56:370-376.
24. Krystal GW, Honsawek S, Litz J, et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000;6:3319-3326.
25. Wang WL, Healy ME, Sattler M, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000;19:3521-3528.
26. Soria JC, Johnson BE, Chevalier TL. Imatinib in small cell lung cancer. Lung Cancer 2003;41(Suppl 1): 549-553.
27. Gersell DJ, Mazoujian G, Mutch DG, et al. Small-cell undifferentiated carcinoma of the cervix: a clinicopathologic, ultrastructural, and immunocytochemical study of 15 cases. Am J Surg Pathol 1988;12:684-698.
28. Perrin L, Ward B. Small cell carcinoma of the cervix. Int J Gynecol Cancer 1995;5:200-203.
29. Straughn Jr JM, Richter HE, Conner MG, et al. Predictors of outcome in small cell carcinoma of the cervix: a case series. Gynecol Oncol 2001;83:216-220.
30. Conner MG, Richter H, Moran CA, et al. Small cell carcinoma of the cervix: a clinicopathologic and immunohistochemical study of 23 cases. Ann Diagn Pathol 2002;6:345-348.
31. Weed Jr JC, Graff AT, Shoup B, et al. Small cell undifferentiated (neuroendocrine) carcinoma of the uterine cervix. J Am Coll Surg 2003;197:44-51.
32. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002;26:1184-1197.
33. Barisella M, Andreola S, Rosai J. CD117 in soft tissue sarcomas. Am J Clin Pathol 2002;118:470-471.
34. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002;117:188-193.
35. Lucas DR, Al-Abbadi M, Tabaczka P, et al. c-Kit expression in desmoid fibromatosis: comparative immunohistochemical evaluation of two commercial antibodies. Am J Clin Pathol 2003;119:339-345.
36. Miettinen M. Are desmoid tumors kit positive [Letter]? Am J Surg Pathol 2001;25:549-550.
37. Montgomery E, Torbenson MS, Kaushal M, et al. β-Catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am J Surg Pathol 2002;26:1296-1301.
38. Yantiss RK, Spiro IJ, Compton CC, et al. Gastrointestinal stromal tumor vs intra-abdominal fibromatosis of the bowel wall: a clinically important differential diagnosis. Am J Surg Pathol 2000;24:947-957.
39. Abeler VM, Holm R, Nesland JM, et al. Small cell carcinoma of the cervix: a clinicopathologic study of 26 patients. Cancer 1994;73:672-677.
40. Ambros RA, Park JS, Shah KV, et al. Evaluation of histologic, morphometric, and immunohistochemical criteria in the differential diagnosis of small cell carcinomas of the cervix with particular reference to human papillomavirus types 16 and 18. Mod Pathol 1991;4:586-593.
41. INK4A overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. Hum Pathol 2003;34:778-783.
42. Lizano M, Berumen J, Guido MC, et al. Association between human papillomavirus type 18 variants and histopathology of cervical cancer. J Natl Cancer Inst 1997;89:1227-1231.
43. Mannion C, Park WS, Man YG, et al. Endocrine tumors of the cervix: morphologic assessment, expression of human papillomavirus, and evaluation for loss of heterozygosity on 1p,3p, 11q, and 17p. Cancer 1998;83:1391-1400.
44. Stoler MH, Mills SE, Gersell DJ, et al. Small-cell neuroendocrine carcinoma of the cervix: a human papillomavirus type 18-associated cancer. Am J Surg Pathol 1991;15:28-32.
45. Wistuba II, Thomas B, Behrens C, et al. Molecular abnormalities associated with endocrine tumors of the uterine cervix. Gynecol Oncol 1999;72:3-9.
46. Cook RM, Miller YE, Bunn Jr PA. Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. Curr Probl Cancer 1993;17:69-141.
47. Rachtan J. Smoking, passive smoking and lung cancer cell types among women in Poland. Lung Cancer 2002;35:129-136.
48. Videtic GMM, Stitt LW, Dar AR, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003;21:1544-1549.
49. Kaye FJ. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene 2002;21:6908-6914.
50. Junker K, Wiethege T, Müller KM. Pathology of small-cell lung cancer. J Cancer Res Clin Oncol 2000;126:361-368.
51. Onuki N, Wistuba II, Travis WD, et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 1999;85:600-607.
52. Gemba K, Ueoka H, Kiura K, et al. Immunohistochemical detection of mutant p53 protein in small-cell lung cancer: relationship to treatment outcome. Lung Cancer 2000;29:23-31.
53. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996;56:4620-4624.
54. Dyson N, Howley PM, Munger K, et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-937.
55. Scheffner M, Huibregtse JM, Vierstra RD, et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495-505.
56. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-1136.
57. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-79.
58. Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567-1572.